Neutrophil to Albumin Ratio: a Biomarker in Non-alcoholic Fatty Liver Disease and with Liver Fibrosis

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2024 Apr 23

PMID 38650638

Authors

Banghe Bao

Shuang Xu

Peng Sun

Liduan Zheng

Affiliations

Soon will be listed here.

Abstract

Objective: Given the high prevalence of non-alcoholic fatty liver disease (NAFLD) and its potential to progress to liver fibrosis, it is crucial to identify the presence of NAFLD in patients to guide their subsequent management. However, the current availability of non-invasive biomarkers for NAFLD remains limited. Therefore, further investigation is needed to identify and develop non-invasive biomarkers for NAFLD.

Methods: A retrospective analysis was conducted on 11,883 patients admitted to the Healthcare Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, from January 2016 to December 2019 and divided into NAFLD and non-NAFLD groups. Anthropometric and laboratory examination data were collected. The correlations between variables and NAFLD were evaluated using the student's t-test or Mann-Whitney U test and binary logistic regression analysis. The predictive ability of these variables for NAFLD was assessed using the areas under the curves (AUCs) of receiver operating characteristics.

Results: Among the included patients, 3,872 (32.58%) were diagnosed with NAFLD, with 386 (9.97%) individuals having liver fibrosis. Patients with NAFLD exhibited a higher proportion of males, elevated body mass index (BMI), and increased likelihood of hypertension, diabetes mellitus, and atherosclerosis. Logistic regression analysis identified the neutrophil to albumin ratio (NAR) as the most promising novel inflammation biomarkers, with the highest AUC value of 0.701, a cut-off value of 0.797, sensitivity of 69.40%, and specificity of 66.00% in identifying the risk of NAFLD. Moreover, NAR demonstrated superior predictive value in identifying NAFLD patients at risk of liver fibrosis, with an AUC value of 0.795, sensitivity of 71.30%, and specificity of 73.60% when NAR reached 1.285.

Conclusion: These findings highlight that the novel inflammatory biomarker, NAR, is a convenient and easily accessible non-invasive predictor for NAFLD and NAFLD with liver fibrosis.

Citing Articles

Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017-2018.

He M, Du X, Liu Y BMC Gastroenterol. 2025; 25(1):20.

PMID: 39833665 PMC: 11744826. DOI: 10.1186/s12876-025-03612-9.

Neutrophil-to-albumin Ratio as a Prognostic Factor in Patients with Acute Ischemic Stroke.

Bao J, Zhang Y, Ma M, Wang J, Jiang X, Guo J Curr Neurovasc Res. 2024; 21(3):300-309.

PMID: 38918991 PMC: 11774307. DOI: 10.2174/0115672026328594240614080241.

References

Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E . Author Correction: Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med. 2022; 28(3):600. DOI: 10.1038/s41591-022-01693-7. View

Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J . Systemic Immune Inflammation Index (SII), System Inflammation Response Index (SIRI) and Risk of All-Cause Mortality and Cardiovascular Mortality: A 20-Year Follow-Up Cohort Study of 42,875 US Adults. J Clin Med. 2023; 12(3). PMC: 9918056. DOI: 10.3390/jcm12031128. View

Wieckowska A, Feldstein A . Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008; 28(4):386-95. DOI: 10.1055/s-0028-1091983. View

De Nardo D, Labzin L, Kono H, Seki R, Schmidt S, Beyer M . High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2013; 15(2):152-60. PMC: 4009731. DOI: 10.1038/ni.2784. View

Khoury T, Mari A, Nseir W, Kadah A, Sbeit W, Mahamid M . Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2019; 31(9):1110-1115. DOI: 10.1097/MEG.0000000000001393. View

Targher G, Byrne C, Tilg H . MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024; 73(4):691-702. DOI: 10.1136/gutjnl-2023-330595. View

Arora U, Biswas S, Aggarwal S, Duseja A, Shalimar . MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature. J Hepatol. 2023; 80(2):e89-e91. DOI: 10.1016/j.jhep.2023.10.032. View

Wong R, Kachru N, Martinez D, Moynihan M, Ozbay A, Gordon S . Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. J Clin Gastroenterol. 2020; 55(10):891-902. PMC: 8500367. DOI: 10.1097/MCG.0000000000001409. View

. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016; 59(6):1121-40. DOI: 10.1007/s00125-016-3902-y. View

10.

Viglino D, Jullian-Desayes I, Minoves M, Aron-Wisnewsky J, Leroy V, Zarski J . Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 2017; 49(6). DOI: 10.1183/13993003.01923-2016. View

11.

Pais R, Giral P, Khan J, Rosenbaum D, Housset C, Poynard T . Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol. 2016; 65(1):95-102. DOI: 10.1016/j.jhep.2016.02.023. View

12.

Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

13.

Rockey D, Caldwell S, Goodman Z, Nelson R, Smith A . Liver biopsy. Hepatology. 2009; 49(3):1017-44. DOI: 10.1002/hep.22742. View

14.

Jiang Y, Zeng J, Chen B . Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. J Gastroenterol Hepatol. 2014; 29(7):1508-14. DOI: 10.1111/jgh.12580. View

15.

Sanal M . Is the change from NAFLD to MASLD driven by political correctness?. J Hepatol. 2023; 80(2):e74-e76. DOI: 10.1016/j.jhep.2023.08.027. View

16.

Huang D, El-Serag H, Loomba R . Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020; 18(4):223-238. PMC: 8016738. DOI: 10.1038/s41575-020-00381-6. View

17.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

18.

Liu C, Chien L . Predictive Role of Neutrophil-Percentage-to-Albumin Ratio (NPAR) in Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Nondiabetic US Adults: Evidence from NHANES 2017-2018. Nutrients. 2023; 15(8). PMC: 10141547. DOI: 10.3390/nu15081892. View

19.

Alfhili M, Alotaibi G, Alfaifi M, Almoghrabi Y, Alsughayyir J . Association of Platelet-Monocyte Ratio with Dyslipidemia in Saudi Arabia: A Large, Population-Based Study. Life (Basel). 2023; 13(8). PMC: 10455526. DOI: 10.3390/life13081685. View

20.

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View